Highlights
Current trends and public-private partnerships in omic profiling for drug saftey assessment.
Today, of the compounds that enter into preclinical development, about 50% currently fail to reach the market due to safety concerns. It is crucial that ultimately unsuccessful compounds fail at the earliest stage possible in order to save long-term costs, free up development resources for more promising compounds, and avoid adverse side effects in patients.
Over the last few years Genedata has been involved in several joint projects with leading pharmaceuticals to address the computational requirements of the approach of systems toxicology – with the goal of early identification of compounds with serious side effects before they reach the clinic.
Genedata currently develops several software modules as part of the Expressionist platform to address the specific requirements of systems toxicology. In particular we are focusing on the standardization of the data collection process to allow users to capture as early as possible all potentially relevant information for identifying compound safety issues. Additionally, Genedata is working on optimizing the prediction of different toxicity classes.
Please check back for the latest developments in systems toxicology at Genedata or contact us to receive more information.
Key Features
- Rapid and standardizable pre-processing and quality assessment of omics raw data
- Flexible integration of diverse data based on common annotations or study design
- Full scalability to large studies with tens of thousands of samples
- Comprehensive analyses for biomarker discovery and in-silico prediction
- Streamlined integration with complementing analysis tools
- Efficient documentation and reporting of analysis results